ASH 2025

from OncoPharm · host John Bossaer

ASH 2025 Highlights: MajesTEC-3: Teclistamab + Daratumumab in relapse refractory Multiple Myeloma Paradigm: HMA + Ven vs. 7+3 or CPX-351 Denosumab safety & dosing in Multiply Myeloma and renal dysfunction Trilaciclib and CDK 4/6 inhibition as protection against TP53-mutated clonal hematopoiesis?

Episode metadata supplied by the publisher feed · Published Dec 11, 2025

Embed this episode

Attribution link and audio player

Ready to play

ASH 2025

0:00 29:05

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncoPharm?

This episode is 29 minutes long.

When was this OncoPharm episode published?

This episode was published on December 11, 2025.

Can I download this OncoPharm episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!